• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,550.25 918.60
( 1.20%)
Global Indices
Nasdaq
47,930.49 -276.32
(-0.57%)
Dow Jones
6,837.38 -8.28
(-0.12%)
Hang Seng
56,916.27 1,020.95
(1.83%)
Nikkei 225
10,596.33 -7.15
(-0.07%)
Forex
USD-INR
92.44 -0.46
(-0.50%)
EUR-INR
107.96 0.52
(0.48%)
GBP-INR
124.05 0.88
(0.72%)
JPY-INR
0.58 0.00
(0.32%)

EQUITY - MARKET SCREENER

Remus Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
78788
INE0O5T01011
205.5515954
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
REMUS
39.02
770.67
EPS(TTM)
Face Value()
Div & Yield %
16.76
10
0.23
 

quest capital markets ltd
Hindustan Unilever board OKs Rs 2,000-cr capex for capacity expansion
Feb 19,2026
The proposed investment is in line with the company’s strategy of focusing on fewer, bigger bets and strengthening its presence in high-growth demand spaces, including premium skin care and hair care and personal care & home care liquids.

Priya Nair, CEO and managing director, HUL, said: 'This investment reflects our strategic focus on scaling our brands and creating categories of the future to meet evolving consumer needs. It also underscores our commitment to building a resilient, technology-enabled supply chain that delivers superior value to consumers.'

Hindustan Unilever is in the FMCG business comprising primarily of Home Care, Beauty & Personal Care and Foods & Refreshment segments. The Company has manufacturing facilities across the country and sells primarily in India.

The company's consolidated net profit zoomed 120.91% to Rs 6,603 crore on 5.74% jump in revenue from operations to Rs 16,235 crore in Q3 FY26 over Q3 FY25.

The counter fell 1.90% to end at Rs 2279.50 on the BSE.